Calidi Biotherapeutics, INC 8-K filings

Calidi Biotherapeutics increases its at-the-market offering with Ladenburg Thalmann & Co. Inc. to a maximum aggregate of $11.2 million.

Calidi Biotherapeutics terminated its Standby Equity Purchase Agreement after raising $18.85 million through public offerings, warrant exercises, and its ATM program, strengthening its cash position.

Calidi Biotherapeutics refiled its 2023 financial statements to reflect a 1-for-10 reverse stock split effective July 15, 2024.

Calidi Biotherapeutics has successfully priced a public offering of 5,000,000 shares of common stock at $0.85 per share, raising gross proceeds of $4.25 million and issuing warrants to the placement agent.

Calidi Biotherapeutics announced data supporting its RTNova technology's potential to target metastatic lung cancer and other oncology indications.

Calidi Biotherapeutics issued warrants to its placement agent, Ladenburg Thalmann & Co., following a $7.5 million public offering of common stock.

Calidi Biotherapeutics reported its Q3 2024 financial results, highlighted by FDA clearance for a NeuroNova clinical trial and a $2 million capital raise.

Calidi Biotherapeutics has successfully priced a $2 million registered direct offering and concurrent private placement to fund working capital and clinical trials.

Calidi Biotherapeutics has released an updated investor presentation on its website, providing new information about the company.

Calidi Biotherapeutics' warrants are set to be delisted from the NYSE American due to their low trading price, while the company's common stock will continue to trade on the exchange.

Calidi Biotherapeutics has entered into an agreement to sell up to $5.1 million of its common stock through an at-the-market offering.

Calidi Biotherapeutics has announced FDA clearance for its CLD-101 clinical trial in high-grade glioma, marking a significant step in the development of its novel stem-cell based immunotherapy.

Calidi Biotherapeutics held its 2024 Annual Meeting, electing Alan Stewart as a Class I Director and ratifying Marcum LLP as its independent auditor.

Calidi Biotherapeutics presented on systemic and localized antitumor virotherapies during a webinar hosted by RedChip Companies, Inc.

Calidi Biotherapeutics has announced the formation of a new wholly owned subsidiary, Redtail Biopharma, Inc., with details provided in a presentation on their website.

Calidi Biotherapeutics announces the departure of board member George Ng at the 2024 annual shareholder meeting, leading to a reduction in the board size.

Calidi Biotherapeutics reported its second quarter 2024 financial results, highlighted by a new patent for its SuperNova technology and strategic investments in its new subsidiary.

Calidi Biotherapeutics has received a $3 million investment, including the launch of a new subsidiary, Nova Cell, focused on regenerative medicine.

Calidi Biotherapeutics has executed a 1-for-10 reverse stock split, effective July 15, 2024, to consolidate its shares.

Calidi Biotherapeutics has entered into a loan agreement for $600,000 with Dennis R. Conklin, bearing a 15% annual interest rate.

Calidi Biotherapeutics will implement a 1-for-10 reverse stock split, effective July 15, 2024, to consolidate its outstanding shares.

Calidi Biotherapeutics has appointed Dr. George Peoples, a renowned surgeon and research scientist, to its Board of Directors, effective July 1, 2024.

Calidi Biotherapeutics' stockholders approved a reverse stock split and several proposals related to the issuance of common stock and warrants at a special meeting on June 6, 2024.

Calidi Biotherapeutics issued warrants to Ladenburg Thalmann & Co., Inc. as part of a financial services agreement related to an inducement offer for existing warrant holders.

Calidi Biotherapeutics has successfully raised approximately $2.1 million through the exercise of existing warrants and issued new warrants for future stock purchases.

Calidi Biotherapeutics has increased the base salary and bonus target for executive Wendy Pizarro, and set a bonus contingent on a successful capital raise.

David LaPre resigned from the Calidi Biotherapeutics Board of Directors and all related committees, effective May 10, 2024.

Calidi Biotherapeutics announced its first quarter 2024 financial results, highlighted clinical and preclinical advancements, and detailed a recent $6.1 million capital raise.

Calidi Biotherapeutics has released updated presentation slides for use in discussions with investors and analysts.

Calidi Biotherapeutics has successfully closed a public offering, raising approximately $6.1 million through the sale of common stock and warrants.